$4.01
0.25% yesterday
Nasdaq, Aug 21, 10:00 pm CET

Cytek BioSciences Inc Stock price

$4.01
+0.91 29.35% 1M
-1.11 21.68% 6M
-2.48 38.21% YTD
-1.37 25.46% 1Y
-9.13 69.48% 3Y
-14.75 78.62% 5Y
-14.75 78.62% 10Y
-14.75 78.62% 20Y
Nasdaq, Closing price Thu, Aug 21 2025
+0.01 0.25%

Key metrics

Basic
Market capitalization
$508.9m
Enterprise Value
$253.1m
Net debt
positive
Cash
$262.0m
Shares outstanding
127.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.6 | 2.5
EV/Sales
1.3 | 1.3
EV/FCF
23.5
P/B
1.4
Financial Health
Equity Ratio
79.2%
Return on Equity
-1.5%
ROCE
-6.4%
ROIC
-11.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$196.0m | $201.9m
EBITDA
$-15.4m | $8.2m
EBIT
$-26.9m | $-32.7m
Net Income
$-6.4m | $-28.2m
Free Cash Flow
$10.8m
Growth (TTM | estimate)
Revenue
-0.8% | 0.7%
EBITDA
11.7% | 181.6%
EBIT
-4.0% | -59.3%
Net Income
63.6% | -368.8%
Free Cash Flow
1.3%
Margin (TTM | estimate)
Gross
54.4%
EBITDA
-7.9% | 4.1%
EBIT
-13.7%
Net
-3.3% | -14.0%
Free Cash Flow
5.5%
More
EPS
$-0.1
FCF per Share
$0.1
Short interest
5.2%
Employees
688
Rev per Employee
$290.0k
Show more

Is Cytek BioSciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,014 stocks worldwide.

Cytek BioSciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a Cytek BioSciences Inc forecast:

7x Buy
64%
4x Hold
36%

Analyst Opinions

11 Analysts have issued a Cytek BioSciences Inc forecast:

Buy
64%
Hold
36%

Financial data from Cytek BioSciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
196 196
1% 1%
100%
- Direct Costs 89 89
0% 0%
46%
107 107
2% 2%
54%
- Selling and Administrative Expenses 95 95
3% 3%
49%
- Research and Development Expense 38 38
9% 9%
19%
-15 -15
12% 12%
-8%
- Depreciation and Amortization 11 11
37% 37%
6%
EBIT (Operating Income) EBIT -27 -27
4% 4%
-14%
Net Profit -6.40 -6.40
64% 64%
-3%

In millions USD.

Don't miss a Thing! We will send you all news about Cytek BioSciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cytek BioSciences Inc Stock News

Neutral
GlobeNewsWire
9 days ago
FREMONT, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced the company will be participating in the following investor conferences.
Neutral
Seeking Alpha
15 days ago
Cytek Biosciences, Inc. (NASDAQ:CTKB ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Paul Goodson - Head of Investor Relations Wenbin Jiang - President, CEO & Chairman of the Board William D. McCombe - Chief Financial Officer Conference Call Participants Chad Wiatrowski - Unidentified Company David Michael Westenberg - Piper Sandler & Co., Research Division Ope...
Neutral
GlobeNewsWire
15 days ago
FREMONT, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Cytek® Biosciences, Inc. (“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the second quarter ended June 30, 2025.
More Cytek BioSciences Inc News

Company Profile

Cytek Biosciences, Inc. is a life sciences technology company engages in the provision of cell analysis tools by leveraging novel technical approaches. Its products include Cytek Aurora CS, Cytek Aurora, Cytek Northern Lights, and Cytek NL-CLC. The company was founded by Wenbin Jiang and Ming Yan in December 2014 and is headquartered in Fremont, CA.

Head office United States
CEO Wen Jiang
Employees 688
Founded 1992
Website cytekbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today